 Connection
Steven Coultrap to Protein Kinase Inhibitors
This is a "connection" page, showing publications Steven Coultrap has written about Protein Kinase Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.379 |
|
|
|
-
Coultrap SJ, Bayer KU. Improving a natural CaMKII inhibitor by random and rational design. PLoS One. 2011; 6(10):e25245.
Score: 0.260
-
Coultrap SJ, Vest RS, Ashpole NM, Hudmon A, Bayer KU. CaMKII in cerebral ischemia. Acta Pharmacol Sin. 2011 Jul; 32(7):861-72.
Score: 0.064
-
Opazo P, Viana da Silva S, Carta M, Breillat C, Coultrap SJ, Grillo-Bosch D, Sainlos M, Coussen F, Bayer KU, Mulle C, Choquet D. CaMKII Metaplasticity Drives A? Oligomer-Mediated Synaptotoxicity. Cell Rep. 2018 06 12; 23(11):3137-3145.
Score: 0.026
-
Buard I, Coultrap SJ, Freund RK, Lee YS, Dell'Acqua ML, Silva AJ, Bayer KU. CaMKII "autonomy" is required for initiating but not for maintaining neuronal long-term information storage. J Neurosci. 2010 Jun 16; 30(24):8214-20.
Score: 0.015
-
Vest RS, O'Leary H, Coultrap SJ, Kindy MS, Bayer KU. Effective post-insult neuroprotection by a novel Ca(2+)/ calmodulin-dependent protein kinase II (CaMKII) inhibitor. J Biol Chem. 2010 Jul 02; 285(27):20675-82.
Score: 0.015
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|